Friederike Braulke
Overview
Explore the profile of Friederike Braulke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT
Muster J, Alt N, Edelmann M, Anczykowski M, Zwerenz C, Schirmer M, et al.
Strahlenther Onkol
. 2025 Mar;
PMID: 40050448
Purpose: In definitive radiotherapy/radiochemotherapy (RT/RCT) for localized non-small cell lung cancer (NSCLC), the introduction of positron-emission tomography (PET)-CT-based staging/RT planning and dynamic RT techniques (intensity-modulated radiotherapy, IMRT/volumetric modulated arc therapy,...
2.
Hampe L, Kuffer S, Niemeier T, Scheele N, Hampe L, Riedl A, et al.
Front Immunol
. 2025 Jan;
15:1509051.
PMID: 39763660
Background: Esophageal cancer has a poor prognosis despite treatment advancements. Although the benefit of neoadjuvant chemoradiotherapy (CRT) followed by adjuvant immunotherapy is evident, the effects of CRT on PD-L1 expression...
3.
Mazzeo P, Ganster C, Wiedenhoft J, Shirneshan K, Rittscher K, Brzuszkiewicz E, et al.
Hemasphere
. 2024 Sep;
8(9):e70014.
PMID: 39315323
The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion of existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important...
4.
Ziegler D, Cleve C, Ziegler S, Schirmer M, Fischer L, Bohnenberger H, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893074
In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years....
5.
Schorb E, Isbell L, Kerkhoff A, Mathas S, Braulke F, Egerer G, et al.
Lancet Haematol
. 2024 Feb;
11(3):e196-e205.
PMID: 38301670
Background: Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of...
6.
Alt N, Muster J, Ziegler D, Bendrich S, Donath S, Hille A, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254817
Identification of the optimal treatment strategy is challenging in elderly with localized non-small cell lung cancer (NSCLC). Concurrent chemotherapy with low-dose cisplatin represents an option for elderly. Outcomes (1) in...
7.
Buchholz S, Nause N, Konig U, Reinecke J, Steuber B, Ammer-Herrmenau C, et al.
J Pers Med
. 2023 Dec;
13(12).
PMID: 38138928
(), also known as (), represents an oncogenic driver and has been effectively targeted in breast and gastric cancer. Recently, next-generation sequencing (NGS) discovered as a promising therapeutic target in...
8.
Evertz R, Diehl C, Godde K, Valentova M, Garfias-Veitl T, Overbeck T, et al.
Sci Rep
. 2023 Sep;
13(1):14861.
PMID: 37684302
Maintaining cancer patients' exercise capacity and therefore patients' ability to live a self-determined life is of huge importance, but little is known about major determinants. We sought to identify determinants...
9.
Braulke F, Kober K, Rieken S, Brand T, Hartz T, Seipke S, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(16):14775-14784.
PMID: 37592032
Purpose: Interdisciplinary tumor boards (ITBs) represent a central part of standard cancer care defining a guidelines-guided treatment plan adapted to the patient's capabilities, comorbidities and wishes in a multi-professional team....
10.
Braulke F, Kober K, Arndt A, Papendick M, Strauss A, Kramm C, et al.
Front Oncol
. 2023 May;
13:1072652.
PMID: 37182140
Introduction: Multi-professional interdisciplinary tumor boards (ITB) are essential institutions to discuss all newly diagnosed, relapsed or complex cancer patients in a team of specialists to find an optimal cancer care...